, Classification of Tumours of Soft Tissue and Bone, pp.281-295, 2013.
, Bone sarcomas: pathogenesis and new therapeutic approaches, vol.8, pp.402-414, 2011.
Osteosarcoma: current status of immunotherapy and future trends, Oncol. Rep, vol.15, pp.693-700, 2006. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667509
Translational biology of osteosarcoma, Nat. Rev. Cancer, vol.14, pp.722-735, 2014. ,
Bone microenvironment signals in osteosarcoma development, Cell Mol. Life Sci, vol.72, pp.3097-3113, 2015. ,
Drugs in early development for the treatment of osteosarcoma, Expert Opin. Invest. Drugs, vol.25, pp.1265-1280, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466096
Concise review: mesenchymal tumors: when stem cells go mad, Stem Cells, vol.29, pp.397-403, 2011. ,
Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells, Bone, vol.62, pp.56-63, 2014. ,
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency, Nat. Commun, vol.6, p.8940, 2015. ,
Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations, Ann. Oncol, vol.27, pp.738-744, 2016. ,
Cancer stem cell niche: the place to be, Cancer Res, vol.71, pp.634-639, 2011. ,
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited, Nat. Rev. Cancer, vol.3, pp.453-458, 2003. ,
Mesenchymal stroma: role in osteosarcoma progression, Cancer Lett, vol.405, pp.90-99, 2017. ,
Cancer stem cells in osteosarcoma, Cancer Lett, vol.386, pp.189-195, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466078
Clonal heterogeneity and tumor evolution: past, present, and the future, Cell, vol.168, pp.613-628, 2017. ,
The biology of normal bone remodelling, Eur J Cancer Care ,
Mechanisms of bone repair and regeneration, Trends Mol. Med, vol.15, pp.417-429, 2009. ,
Osteoclastic acidification pathways during bone resorption, Bone, vol.30, pp.533-540, 2002. ,
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodelling, Cytokine Growth Factor Rev, vol.15, pp.457-475, 2004. ,
, key partners of osteoimmunology and vascular diseases, vol.4, pp.2334-2350, 2007.
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, vol.93, pp.165-176, 1998. ,
Canonical and non-canonical pathways of osteoclast formation, Histol. Histopathol, vol.24, pp.337-346, 2009. ,
Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis, J. Pathol, vol.221, pp.77-86, 2010. ,
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, vol.390, pp.175-179, 1997. ,
TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor, J. Exp. Med, vol.186, pp.2075-2080, 1997. ,
, Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond, vol.5, p.511, 2014.
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems, Nat. Rev. Immunol, vol.7, pp.292-304, 2007. ,
RANK-RANKL signalling in cancer, Biosci. Rep, vol.36, p.366, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01644732
, RANKL blockade prevents and treats aggressive osteosarcomas, vol.7, pp.317-197, 2015.
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis, Am. J. Pathol, vol.163, pp.2021-2031, 2003. ,
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B, J. Pathol, vol.211, pp.555-562, 2007. ,
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models, J. Bone Miner. Res, vol.26, pp.2452-2462, 2011. ,
Osteoprotegerin regulates cancer cell migration through SDF-1/CXCR4 axis and promotes tumour development by increasing neovascularization, Cancer Lett, vol.395, pp.11-19, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02327123
Monoclonal antibodies targeting RANKL in bone metastasis treatment, Future Medicine Ltd, pp.42-53, 2012. ,
RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?, Oncology, vol.88, pp.257-260, 2015. ,
Increased osteoclast activity is associated with aggressiveness of osteosarcoma, Int. J. Oncol, vol.33, pp.1231-1238, 2008. ,
The role of osteoclasts and tumourassociated macrophages in osteosarcoma metastasis, Biochim. Biophys. Acta, vol.2012, pp.434-442, 1826. ,
Inflammatory osteoclasts prime TNF?producing CD4 + T cells and express CX 3 CR1, J. Bone Miner. Res, vol.31, pp.1899-1908, 2016. ,
Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence, PLoS One, vol.5, p.10999, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667931
Prognostic value of inflammation-based scores in patients with osteosarcoma, Sci. Rep, vol.6, p.39862, 2016. ,
Pre-operative lymphocyte-to-monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma, FEBS Open Biol, vol.5, pp.682-687, 2015. ,
, Clin. Sarcoma Res, vol.6, p.13, 2016.
Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma, Oncotarget, vol.7, pp.78343-78354, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466103
Osteoblast-like cell line maintains in vitro rat peritoneal mast cell viability and functional activity, Immunology, vol.69, pp.145-149, 1990. ,
Mast cells in atherosclerosis as a source of the cytokine RANKL, Clin. Chem. Lab. Med, vol.44, pp.672-674, 2006. ,
Mast cells are critical regulators of bone fracture-induced inflammation and osteoclast formation and activity, J. Bone Miner. Res ,
Tumor-associated mesenchymal stromal cells promote osteosarcoma stemness and migratory potential via IL-6 secretion, PLoS One, vol.11, p.166500, 2016. ,
Adipose-derived mesenchymal stem cells promote osteosarcoma proliferation and metastasis by activating the STAT3 pathway, Oncotarget, vol.8, pp.23803-23816, 2017. ,
Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3, Oncotarget, vol.7, pp.48296-48308, 2016. ,
Bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion, World J. Surg. Oncol, vol.13, p.52, 2015. ,
Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip, Eur. J. Cell. Biol, vol.96, pp.110-118, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466071
Mesenchymal/stem stromal cells under stress increase osteosarcoma migration and apoptosis resistance via extracellular resistance via extracellular vesicle mediated communication, PLoS One, vol.11, p.166027, 2016. ,
Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-?B activation, Int. J. Cancer, vol.140, pp.1331-1345, 2017. ,
Multimodal transfer of MDR by exosomes in human osteosarcoma, Int. J. Oncol, vol.49, pp.189-196, 2016. ,
Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression, Clin. Cancer Res, vol.23, pp.3721-3733, 2017. ,
Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment, J. Inflamm. Res, vol.9, pp.231-240, 2016. ,
Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide, Cell Stem Cell, vol.2, pp.141-150, 2008. ,
Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization, Stem Cells Transl. Med, vol.6, pp.1018-1028, 2017. ,
Macrophages and skeletal health, Pharmacol. Ther, vol.174, pp.3-54, 2017. ,
Proteoglycans and osteolysis, Methods Mol. Biol, vol.836, pp.323-337, 2012. ,
Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling, Stem Cells, vol.30, pp.762-772, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00668995
Alternative activation of macrophages: mechanism and functions, Immunity, vol.32, pp.593-604, 2010. ,
Distinct role of macrophages in different tumor microenvironments, Cancer Res, vol.66, pp.605-612, 2006. ,
Tumor-associated macrophages: from mechanisms to therapy, Immunity, vol.41, pp.49-61, 2014. ,
Macrophage diversity enhances tumor progression and metastasis, Cell, vol.141, pp.39-51, 2010. ,
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents, Clin. Cancer Res, vol.17, pp.2110-2119, 2011. ,
CD163 + M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma, Int. Immunopharmacol, vol.34, pp.101-106, 2016. ,
Increased CTLA-4 + T cells and an increased ratio of monocytes with loss of class II (CD14 + HLA-DR lo/neg ) found in aggressive pediatric sarcoma patients, J. Immunother. Cancer, vol.3, p.35, 2015. ,
, Tim3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients, vol.44, pp.153-159, 2017.
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma trhough induction of angiogenesis and macrophage recruitment, Int. J. Cancer, vol.137, pp.73-85, 2015. ,
Improved survival in osteosarcoma patients with atypical low vascularisation, Ann. Surg. Oncol, vol.22, pp.489-496, 2015. ,
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, Expert Rev. Anticancer Ther, vol.8, pp.151-159, 2008. ,
Mifamurtide for the treatment of nonmetastatic osteosarcoma, Expert Opin. Pharmacother, vol.12, pp.285-292, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00667530
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-?, J. Exp. Clin. Cancer Res, vol.33, p.27, 2014. ,
All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages, Cancer Immunol. Res, vol.5, pp.547-559, 2017. ,
Antitumor and antimetastatic actions of dihydroxycoumarins (esculetin or fraxetin) through the inhibition of M2 macrophage differentiation in tumor-associated macrophages and/or G1 arrest in tumor cells, Eur. J. Pharmacol, vol.746, pp.115-125, 2015. ,
Oncolytic adnovirus as a therapeutic approach for osteosarcoma: a new hope, J. Bone Oncol ,
Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation, Cancer Res, vol.73, pp.490-495, 2013. ,
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma, Sci. Rep, vol.6, p.30093, 2016. ,
, CD8 + /FOXP3 + ration in osteosarcoma microenvironment separates survivors from non-survivors: a multicentre validated retrospective study, vol.4, p.990800, 2015.
Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma, J. Vet. Intern. Med, vol.24, pp.1118-1123, 2010. ,
Tumor-infiltrating lymphocytes for the treatment of metastatic cancer, Mol. Oncol, vol.9, pp.1918-1935, 2015. ,
Exploiting the curative potential of adoptive T-cell therapy for cancer, Immunol. Rev, vol.257, pp.56-71, 2014. ,
Phenotypic and functional analysis of 3ymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype, Cancer Immunol. Immunother, vol.34, pp.241-251, 1992. ,
Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma, BMC Cancer, vol.5, p.123, 2005. ,
The B7 family and cancer therapy: costimulation and coinhibition, Clin. Cancer Res, vol.13, pp.5271-5279, 2007. ,
, Coinhibitory pathways in the B7-CD28 ligand-receptor family, vol.44, pp.955-972, 2016.
Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice, Genet. Mol. Res, vol.14, pp.14253-14261, 2015. ,
B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis, PLoS One, vol.8, p.70689, 2013. ,
Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors ,
Programmed cell death ligand 1 expression in osteosarcoma, Cancer Immunol. Res, vol.2, pp.690-698, 2014. ,
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy, Cancer Immunol. Immunother, vol.66, pp.119-128, 2017. ,
Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+lymphocytes in primary sarcomas is subtype dependent ,
Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis, Oncotarget, 2017. ,
Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma, PLoS One, vol.11, p.157176, 2016. ,
Expression of programmed death 1 is correlated with progression of osteosarcoma, APMIS, vol.123, pp.102-107, 2015. ,
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions, J. Immunother, vol.38, pp.96-106, 2015. ,
Potential of human ?? T cells for immunotherapy of osteosarcoma, Mol. Biol. Rep, vol.40, pp.427-437, 2013. ,
Bisphosphonates, new therapeutic agents for the treatment of bone tumors, Trends Mol. Med, vol.10, pp.337-343, 2004. ,
Trastuzumab enhanced the cytotoxicity of V?9V?2 T cells against zoledronate-sensitized osteosarcoma cells, Int. Immunopharmacol, vol.28, pp.160-167, 2015. ,
Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells, Cell Immunol, vol.249, pp.63-72, 2007. ,
Sensitization of human osteosarcoma cells to V?9V?2 T-cell-mediated cytotoxicity by zoledronate, J. Orthop. Res, vol.30, pp.824-830, 2012. ,
IFN-? enhances HOS and U2OS cell lines susceptibility to ?? T cell-mediated killing through the Fas/Fas ligand pathway, Int. Immunopharmacol, vol.11, pp.496-503, 2011. ,
?? T cells: unexpected regulators of cancer development and progression, Trends Cancer, vol.3, pp.561-570, 2017. ,
Genetically modified T-cell therapy for osteosarcoma, Adv. Exp. Med. Biol, vol.804, pp.323-340, 2014. ,
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression, Mol. Ther, vol.17, pp.1779-1787, 2009. ,
Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma, Cancer Gene Ther, vol.19, pp.212-217, 2012. ,
Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats, Cancer Res, vol.68, pp.9433-9440, 2008. ,
In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma, Oncol. Lett, vol.12, pp.1101-1106, 2016. ,
Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma, Oncol. Rep, vol.34, pp.1995-2001, 2015. ,
Anti-TGF-? antibody combined with dendritic cells produce antitumor effects in osteosarcoma, Clin. Orthop. Relat. Res, vol.470, pp.2288-2294, 2012. ,
Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response, Genet. Mol. Res, vol.14, pp.11763-11770, 2015. ,
A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma, Cancer Immunol. Immunother, vol.64, pp.1251-1260, 2015. ,
Natural killer cells for osteosarcoma, Adv. Exp. Med. Biol, vol.804, pp.341-353, 2014. ,
Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner, Cancer Lett, vol.368, pp.54-63, 2015. ,
Aerosol delivery of interleukin-2 in combination with adoptive transfer of natural killer cells for the treatment of lung metastasis: methodology and effect, Methods Mol. Biol, vol.1441, pp.285-295, 2016. ,
Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells, Cancer Immunol. Immunother, vol.60, pp.575-586, 2011. ,
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis, Pediatr. Blood Cancer, vol.61, pp.1362-1368, 2014. ,
Invariant NKT cells increase drug-induced osteosarcoma cell death, Br. J. Pharmacol, vol.167, pp.1533-1549, 2012. ,
Patient-derived tumor xenografts: transforming clinical samples into mouse models, Cancer Res, vol.73, pp.5315-5319, 2013. ,
Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts, Nat. Rev. Cancer, vol.15, pp.451-452, 2015. ,
Patient-Derived Mouse Models of Cancer, Molecular and Translational Medicine Series, 2017. ,
Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics, Genome Med, vol.6, p.116, 2014. ,
A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology, Oncotarget, vol.8, pp.62111-62119, 2017. ,
Establishment of a patient-derived orthotopic osteosarcoma mouse model, J. Transl. Med, vol.13, p.136, 2015. ,
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug, Oncotarget, vol.8, pp.8035-8042, 2017. ,
Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model, Cell Cycle, vol.16, pp.1164-1170, 2017. ,
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model, Nat. Commun, vol.8, p.707, 2017. ,